Kidney Week

Abstract: FR-PO1053

Effects of Sulforaphane Supplementation on Gut Microbiota in Nondialysis-Dependent Patients with CKD

Session Information

• Kidney Nutrition and Metabolism
  October 25, 2024 | Location: Exhibit Hall, Convention Center
  Abstract Time: 10:00 AM - 12:00 PM

Category: Health Maintenance, Nutrition, and Metabolism

• 1500 Health Maintenance, Nutrition, and Metabolism

Authors

• Mafra, Denise, Universidade Federal Fluminense, Niteroi, Rio de Janeiro, Brazil

Denise Mafra, PhD

• Ribeiro, Marcia Maria, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil

Marcia Maria Ribeiro, PhD

• Britto, Isadora, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil

Isadora Britto, MS

• de Paiva, Bruna Regis, Universidade Federal Fluminense, Niteroi, Rio de Janeiro, Brazil

Bruna Regis de Paiva, PhD

• Cardozo, Ludmila Fmf, Universidade Federal Fluminense, Niteroi, Rio de Janeiro, Brazil

Ludmila Fmf Cardozo, PhD

• de Almeida, Pedro Ivo Neves, Fundacao Oswaldo Cruz, Rio de Janeiro, RJ, Brazil

Pedro Ivo Neves de Almeida, MMSc, PhD

• Santos, Henrique Fragoso dos, Universidade Federal Fluminense, Niteroi, Rio de Janeiro, Brazil

Henrique Fragoso dos Santos, PhD

Background

Gut dysbiosis is associated with systemic inflammation and the accumulation of uremic toxins. Sulforaphane isothiocyanate (SFN) is a bioactive compound derived from cruciferous vegetables that may mitigate gut dysbiosis. SFN has anti-inflammatory and antioxidant properties, improving permeability and intestinal function and impacting dysbiosis. This study aimed to explore the effects of SFN supplementation on gut microbiota in patients with CKD.

Methods

This study was a placebo-controlled longitudinal study. The patients were randomly assigned to either the intervention group, which received 400 ug/day of SFN, or the placebo group, which received corn starch for 30 days. We assessed the fecal microbiome using high-throughput sequencing of 16S rRNA gene amplicons on the Illumina MiSeq platform. The data was processed using the QIIME 2 software package. We calculated the alpha diversity using RStudio and the phyloseq library. We used a network of nodes and edges to represent the genus-level taxa and the correlations between them. We analyzed the co-occurrence patterns using the SparCC algorithm and the SpiecEasi library in R. The PageRank algorithm was used to identify the core members of each microbiome. We performed Kruskal-Wallis and PERMANOVA tests to analyze differences between profiles.

Results

16 patients participated (12 women, age 61.4 ± 11.6 years, BMI 30.1 ± 7.0 kg/m², and glomerular filtration of 37.4 ± 12.9 mL/min). We constructed gender co-occurrence networks for SFN and placebo groups. After the intervention, the frequency of genera Bacteroidetes, Firmicutes, and Proteobacteria was reduced (Fig 1).

Conclusion

The intervention simplified the co-occurrence network of microbial generation in the gut of non-dialysis CKD patients. Expressing the ability of SFN to modify the diversity of the gut microbiota.

Fig 1. Co-occurrence measures in patients who received SFN

Funding

• Government Support – Non-U.S.